Damora Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DMRA research report →
Range $40 – $60
Price Chart
About the company
Damora Therapeutics, Inc. , a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
- CEO
- Jennifer A. Jarrett
- IPO
- 2020
- Employees
- 7
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on DMRA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.44B
- P/E
- -0.19
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 2.94
- EV/EBITDA
- -3.70
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -66.20%
- ROIC
- -61.25%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-210,872,000
- Net Income
- $-209,839,000-878.8%
- EPS
- $-152.99-725.6%
- OCF Growth
- +63.9%
- FCF Growth
- +63.9%
- 52W High
- $38.33
- 52W Low
- $15.76
- 50D MA
- $21.79
- 200D MA
- $25.44
- Beta
- 1.51
- RSI (14)
- 56
- Avg Volume
- 576.73K
No earnings-call transcripts are available for DMRA yet.
- Free Float
- 67.1%
- Shares Outstanding
- 61.90M
- Float Shares
- 41.56M
of shares held by institutions
103 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 9.55M | ▲ 316.08K |
| Fairmount Funds Management LLC | 8.71M | 0 |
| Avoro Capital Advisors LLC | 3.78M | 0 |
| Venrock Adviser, LLC | 3.60M | 0 |
| Blackrock, Inc. | 3.51M | ▲ 352.50K |
| Fcpm Iii Services B.V. | 2.44M | 0 |
| Ra Capital Management, L.P. | 2.40M | 0 |
| Jupiter Topco LLC | 2.28M | ▲ 2.28M |
| Remedium Capital Partners, LLC | 2.05M | 0 |
| Commodore Capital LP | 1.94M | 0 |
| Bellevue Group AG | 1.92M | ▲ 300.54K |
| Jpmorgan Chase & Co | 1.87M | ▼ 186.31K |
Held by 182 ETFs
Biggest fund positions in DMRA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 25, 26 | Jarrett Jennifer | buy | 12,500 |
| Aug 12, 26 | Cheng Andrew | other | 30,350 |
| Aug 12, 26 | Cheng Andrew | other | 0 |
| Jul 3, 26 | Winslow Garrett | other | 680 |
| Jul 6, 26 | Winslow Garrett | sell | 245 |
| Jul 3, 26 | Winslow Garrett | other | 680 |
| May 1, 26 | Burkavage Brian | other | 0 |
| Mar 30, 26 | Jarrett Jennifer | other | 1,500,000 |
| Mar 30, 26 | Jarrett Jennifer | other | 500,000 |
| Mar 30, 26 | Jarrett Jennifer | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DMRA coverage
Recent articles, reports, and earnings notes.
No research on DMRA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DMRA report →Damora Therapeutics, Inc. (DMRA) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Breaks Above 50 Day Moving Average After Analyst Downgrade
defenseworld.net · Nov 17
Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
globenewswire.com · Nov 4
Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting
globenewswire.com · Nov 4
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Gap Down – Time to Sell?
defenseworld.net · Oct 3
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Oct 2
Damora CEO buys 12,500 shares in open market
defenseworld.net · Sep 29
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) CEO Jennifer Jarrett Purchases 12,500 Shares of Company Stock
defenseworld.net · Sep 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.